(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its upcoming annual meeting, citing concerns about certain changes ...

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest.

Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express concern about the FDA’s future; Pfizer’s obesity setback could be Viking’s ...

CEO Albert Bourla made a “pragmatic and thoughtful” assessment of the company when he approached Baum in early 2024, Baum told the crowd at STAT’s Breakthrough Summit East Thursday.

Pfizer PFE-1.48%decrease; red down pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle. So ...

A third person is expected to be interviewed soon, though Pfizer executives have not yet been questioned. Pfizer maintains that its vaccine development was driven purely by science and regulatory ...